First-Order Elimination Kinetics

1988 ◽  
Vol 7 (2) ◽  
pp. 183-186 ◽  
Author(s):  
J.E. Bright ◽  
T.C. Marrs

The pharmacokinetics of intravenously injected potassium cyanide have been studied in Beagle bitches. In the period up to about 80 min after dosing, blood levels fell in a manner consistent with first-order elimination kinetics. Thereafter blood cyanide concentrations fell at a slower rate, indicating that a second phase of slower elimination had been entered.


1974 ◽  
Vol 8 (8) ◽  
pp. 462-469
Author(s):  
Wayne A. Kradjan

Although the majority of individuals medicated with diphenylhydantoin require doses in the range of 4–6 mg/kg/day (300–400 mg/day), there are many people who are known to deviate from this average in their requirements. Other persons may be stablized on a given dose of diphenylhydantoin, yet develop toxic signs or demonstrate lack of therapeutic effect at a later time. This paper reviews basic pharmacokinetics and elimination data for diphenylhydantoin, as well as the various parameters recognized as influencing diphenylhydantoin dosing requirements. A case history is presented1 to illustrate the possible effects of renal failure and how one individual's requirements changed as his clinical status changed. Among the physiological factors considered are liver function, renal function, genetic influences on metabolic disposition, and alterations that occur in serum protein binding of diphenylhydantoin. Physical characteristics that are considered include variability in formulation of various solid oral dosage forms, hazards of oral suspensions of diphenylhydantoin, efficacy of intramuscular injections, and failure of diphenylhydantoin to obey first order elimination kinetics. Finally, interaction of other drug products with diphenylhydantoin is discussed and summarized.


Author(s):  
Joris C Verster ◽  
Thomas M. Tzschentke ◽  
Kieran O’Malley ◽  
Francis C Colpaert ◽  
Bart Ellenbroek ◽  
...  

2019 ◽  
Vol 80 (12) ◽  
pp. 2250-2259
Author(s):  
Xiaoyu Deng ◽  
Dachao Zhang ◽  
Meng Wu ◽  
Philip Antwi ◽  
Hao Su ◽  
...  

Abstract Aerofloats, such as aniline aerofloat ((C6H5NH)2PSSH), are extensively employed for collection activities in wastewater particularly in cases where minerals are in flotation. Although this aniline aerofloat has efficient collection properties, they are ordinarily biologically persistent chemicals in which case their residual, as well as their byproducts, pose great environmental risks to water and soils. In this study, the removal efficiency of aniline aerofloat (AAF) by a combined vacuum ultraviolet (VUV) and ozone (O3) process (VUV/O3) was evaluated. Furthermore, the impacts of pH, O3, the concentration of AAF and coexisting ions (SiO32−, CO32−, Cl− (Na+), SO42−, Ca2+) were systematically studied. The experiments revealed that, with an initial AAF of 15 mg/L, AAF removal >88% was feasible with a reaction time of 60 min, pH of 8 and O3 of 6 g/h. The order of influence of the selected coexisting ions on the degradation of AAF by VUV/O3 was Ca2+ > CO32− > SiO32− > Cl− (Na+) >SO42−. Compared with VUV and O3 in terms of pollutant degradation rate, VUV/O3 showed a remarkable performance, followed by O3 and VUV. Additionally, the degradation kinetics of AAF by the VUV/O3 process agreed well with first-order elimination kinetics.


1986 ◽  
Vol 15 (7) ◽  
pp. 843-846 ◽  
Author(s):  
Richard Gerkin ◽  
Steven C Curry ◽  
Michael V Vance ◽  
Paul W Sankowski ◽  
Robert D Meinhart

1996 ◽  
Vol 36 (1) ◽  
pp. 25-34 ◽  
Author(s):  
Suneel K. Gupta ◽  
Stephen Hwang ◽  
Linda Atkinson ◽  
James Longstreth

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 203
Author(s):  
Ju Hee Kim ◽  
Dong Wook Kang ◽  
Go-Wun Choi ◽  
Sang Bok Lee ◽  
Seongjin Lee ◽  
...  

Lidocaine-incorporated hyaluronic acid injection (LHA) is considered a promising way to increase patient compliance. Various reviews and analyses have been conducted to verify that the addition of lidocaine had no effect on the product quality of hyaluronic acid injections. However, possible pharmacokinetic (PK) alterations of lidocaine and its active metabolites, monoethylglycylxylidide (MEGX) and glycylxylidide (GX), in hyaluronic acid injection have not been studied so far. Thus, the objective of this study was to evaluate lidocaine and its metabolite PK after 0.3% lidocaine solution or LHA injection and to investigate any changes in PK profiles of lidocaine and its active metabolites. To do this, a novel bio-analytical method for simultaneous determination of lidocaine, MEGX, and GX in rat plasma was developed and validated. Then, plasma concentrations of lidocaine and its active metabolites MEGX and GX following subcutaneous (SC) injection of 0.3% lidocaine solution or LHA with 0.3–1% lidocaine in male Sprague-Dawley rats were successfully determined. The obtained data were used to develop a parent-metabolite pharmacokinetic (PK) model for LHA injection. The half-life, dose-normalized Cmax, and AUCinf of lidocaine after SC injection of lidocaine solution and LHA did not show statistically significant difference. The PK characteristics of lidocaine after LHA administration were best captured using a two-compartment model with combined first-order and transit absorption and its clearance described with Michaelis–Menten and first-order elimination kinetics. Two one-compartment models were consecutively added to the parent model for the metabolites. In conclusion, the incorporation of lidocaine in hyaluronic acid filler injection did not alter the chemical’s pharmacokinetic characteristics.


Sign in / Sign up

Export Citation Format

Share Document